Comparing two new treatments for axial spondyloarthritis after a TNF inhibitor fails
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of axial spondyloarthritis (including ankylosing spondylitis).
- Your disease is active, meaning you have significant pain, stiffness, or other symptoms.
- You have tried at least one TNF inhibitor (a type of biologic) and it did not work or you could not tolerate it.
- You have not used an IL-17 inhibitor or a JAK inhibitor before.
- You are not currently taking other biologic or targeted synthetic disease-modifying drugs.
- You do not have certain health conditions like inflammatory bowel disease, active cancer, recent stroke, heart attack, blood clots, cirrhosis, or severe kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication that may reduce inflammation and improve symptoms in people with axial spondyloarthritis. It is in early phases, meaning the drug is still being studied for safety and effectiveness.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
This study tests whether the medicine upadacitinib (a pill that reduces inflammation) can reduce the number of acute uveitis flare-ups (eye inflammation) in people with axial spondyloarthritis (a type of arthritis affecting the spine). It may help prevent these painful eye episodes if you have them alongside your arthritis.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
Hear when a new Axial Spondyloarthritis (AxSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.